Clinical Pharmacokinetics of the BCR–ABL Tyrosine Kinase Inhibitor Nilotinib

[1]  A. Stead,et al.  Effects of food on the relative bioavailability of lapatinib in cancer patients. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[2]  Richard Pazdur,et al.  Tasigna for Chronic and Accelerated Phase Philadelphia Chromosome–Positive Chronic Myelogenous Leukemia Resistant to or Intolerant of Imatinib , 2008, Clinical Cancer Research.

[3]  S. Yamashita,et al.  Rate-Limiting Steps of Oral Absorption for Poorly Water-Soluble Drugs in Dogs; Prediction from a Miniscale Dissolution Test and a Physiologically-Based Computer Simulation , 2008, Pharmaceutical Research.

[4]  H. Kantarjian,et al.  Dasatinib pharmacokinetics and exposure-response (E-R): Relationship to safety and efficacy in patients (pts) with chronic myeloid leukemia (CML) , 2008 .

[5]  J. Radich,et al.  Nilotinib (formerly AMN107), a highly selective BCR-ABL tyrosine kinase inhibitor, is active in patients with imatinib-resistant or -intolerant accelerated-phase chronic myelogenous leukemia. , 2008, Blood.

[6]  R. Larson,et al.  Nilotinib in Patients (pts) with Philadelphia Chromosome-Positive (Ph+) Chronic Myelogenous Leukemia in Blast Crisis (CML-BC) Who Are Resistant or Intolerant to Imatinib. , 2007 .

[7]  K. Bhalla,et al.  Nilotinib (formerly AMN107), a highly selective BCR-ABL tyrosine kinase inhibitor, is effective in patients with Philadelphia chromosome-positive chronic myelogenous leukemia in chronic phase following imatinib resistance and intolerance. , 2007, Blood.

[8]  Hans Lennernäs,et al.  Modeling gastrointestinal drug absorption requires more in vivo biopharmaceutical data: experience from in vivo dissolution and permeability studies in humans. , 2007, Current drug metabolism.

[9]  Philippe Broët,et al.  Constitutive phosphoinositide 3-kinase/Akt activation represents a favorable prognostic factor in de novo acute myelogenous leukemia patients. , 2007, Blood.

[10]  H. Kantarjian,et al.  Outcome of patients with Philadelphia chromosome‐positive chronic myelogenous leukemia post‐imatinib mesylate failure , 2007, Cancer.

[11]  Doriano Fabbro,et al.  Structural biology contributions to the discovery of drugs to treat chronic myelogenous leukaemia , 2006, Acta crystallographica. Section D, Biological crystallography.

[12]  K. Bhalla,et al.  Nilotinib in imatinib-resistant CML and Philadelphia chromosome-positive ALL. , 2006, The New England journal of medicine.

[13]  J. Mestan,et al.  AMN107 (nilotinib): a novel and selective inhibitor of BCR-ABL , 2006, British Journal of Cancer.

[14]  M. Debiec‐Rychter,et al.  Cellular Uptake of the Tyrosine Kinase Inhibitors Imatinib and AMN107 in Gastrointestinal Stromal Tumor Cell Lines , 2006, Pharmacology.

[15]  M. Sattler,et al.  Novel targeted therapies to overcome imatinib mesylate resistance in chronic myeloid leukemia (CML). , 2006, Critical reviews in oncology/hematology.

[16]  Jooil Kim,et al.  Food-Effect Bioavailability and Fed Bioequivalence Studies , 2005 .

[17]  V. Fischer,et al.  Safety, Pharmacokinetics (PK), Metabolism, and Mass Balance of [14C]-AMN107, a Novel Aminopyrimidine Inhibitor of Bcr-Abl Tyrosine Kinase, in Healthy Subjects. , 2005 .

[18]  Donna Neuberg,et al.  Characterization of AMN107, a selective inhibitor of native and mutant Bcr-Abl. , 2005, Cancer cell.

[19]  A. Racine‐Poon,et al.  Pharmacokinetics and pharmacodynamics of imatinib in a phase I trial with chronic myeloid leukemia patients. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[20]  W. Colburn,et al.  Thalidomide Dose Proportionality Assessment following Single Doses to Healthy Subjects , 2001, Journal of clinical pharmacology.

[21]  W. L. Chiou,et al.  Similarity in the linear and non-linear oral absorption of drugs between human and rat. , 2000, International journal of clinical pharmacology and therapeutics.

[22]  Brahma N. Singh,et al.  Effects of Food on the Clinical Pharmacokinetics of Anticancer Agents , 2004, Clinical pharmacokinetics.